Efficacy of preoperative inhaled LAMA/LABA combinations in patients with lung cancer and untreated COPD

被引:0
|
作者
Mizuno, Yoshimasa [1 ]
Shirahashi, Koyo [2 ]
Yamamoto, Hirotaka [2 ]
Matsumoto, Mitsuyoshi [2 ]
Miyamoto, Yusaku [2 ]
Komuro, Hiroyasu [2 ]
Hagiwara, Kiyohiko [2 ]
Doi, Kiyoshi [2 ]
Iwata, Hisashi [3 ]
机构
[1] Chuno Kosei Hosp, Dept Gen Thorac Surg, Wakakusa Dori 5-1, Seki 5013802, Japan
[2] Univ Gifu, Grad Sch Med, Dept Gen & Cardiothorac Surg, Gifu, Japan
[3] Univ Hosp Gifu, Ctr Resp Dis, Dept Gen Thorac Surg, Gifu, Japan
来源
MINERVA SURGERY | 2021年 / 76卷 / 06期
关键词
Lung neoplasms; Thoracic surgery; Pulmonary disease; chronic obstructive; Bronchodilator agents; Drug combinations; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY COMPLICATIONS; TIOTROPIUM; RESECTION; SURGERY; TRENDS; IMPACT;
D O I
10.23736/S2724-5691.21.08717-79
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is associated with a high incidence of postoperative pulmonary complications (PPCs). When untreated COPD is found before lung cancer surgery, we have been actively intervening therapeutically with inhaled long-acting muscarinic antagonist (LAMA)/long-acting beta 2-agonist (LABA) combinations. We investigated the efficacy of preoperative LAMA/LABA treatment. METHODS: We reviewed data from 261 patients who underwent pulmonary resection for primary lung cancer. Of these, 59 patients showed unrecognized obstructive ventilatory impairment on respiratory function testing. We administered inhaled drugs for 38 patients, of whom 22 patients treated with LAMA/LABA combinations and diagnosed with COPD were retrospectively analyzed regarding improvement of respiratory function and postoperative course. RESULTS: Median duration of LAMA/LABA treatment was 19.5 days (interquartile range (IQR), 10.5-28.3 days). Percentage predicted vital capacity (%VC) (pretreatment: 95.6%, IQR 91.9-111.7 vs. posttreatment 102.8%, IQR 92.3113.0), forced expiratory volume in 1 s (FEV1) (1.76 L, 1.43-2.12 vs. 2.00 L, 1.78-2.40), forced VC (FVC) (2.96 L, 2.64-3.47 vs. 3.22 L, 2.95-3.74) and percentage predicted FEV1 (80.1%, 68.4-97.0 vs. 91.6%, 80.3-101.9) were all significantly improved (P 0.05 each). FEV1/FVC tended to be improved, but not significantly. No significant difference in improvement of respiratory function was seen between short-term (<= 2 weeks) and normal-term ( 2 weeks) treatment. PPCs occurred in 4 of 22 patients (18.2%), showing no significant difference compared to patients with COPD previously treated with inhaled drugs (2/20; 10.0%). CONCLUSIONS: Respiratory function is improved by preoperative LAMA/LABA treatment even in the short term. Starting treatment allows even COPD patients diagnosed on preoperative screening to experience the same frequency of PPCs as previously treated patients.
引用
收藏
页码:592 / 597
页数:6
相关论文
共 50 条
  • [1] Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD
    Kobayashi, Seiichi
    Suzuki, Satoshi
    Niikawa, Hiromichi
    Sugawara, Takafumi
    Yanai, Masaru
    RESPIROLOGY, 2009, 14 (05) : 675 - 679
  • [2] LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
    Rodrigo, Gustavo J.
    Price, David
    Anzueto, Antonio
    Singh, Dave
    Altman, Pablo
    Bader, Giovanni
    Patalano, Francesco
    Fogel, Robert
    Kostikas, Konstantinos
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 907 - 922
  • [3] Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Wu, David Bin-Chia
    Pearce, Fiona
    Chua, Gerald Seng Wee
    Lin, Liang
    Tan, Ping-Tee
    Ng, Kwong
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3203 - 3231
  • [4] Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
    Gong, Yiwen
    Lv, Yinghua
    Liu, Hongxia
    Zheng, Qingshan
    Li, Lujin
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [5] Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD
    Banerji, Donald
    Mahler, Donald A.
    Hanania, Nicola A.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (07) : 767 - 780
  • [6] Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease
    Azuma, Yoko
    Sano, Atsushi
    Sakai, Takashi
    Koezuka, Satoshi
    Otsuka, Hajime
    Tochigi, Naobumi
    Isobe, Kazutoshi
    Sakamoto, Susumu
    Takai, Yujiro
    Iyoda, Akira
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [7] Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
    D'Urzo, Anthony
    Chapman, Kenneth R.
    Donohue, James F.
    Kardos, Peter
    Maleki-Yazdi, M. Reza
    Price, David
    PULMONARY THERAPY, 2019, 5 (01) : 23 - 41
  • [8] Use of ICS/LABA Combinations or LAMA Is Associated with a Lower Risk of Acute Exacerbation in Patients with Coexistent COPD and Asthma
    Su, Vincent Yi-Fong
    Yang, Kuang-Yao
    Yang, Yao-Hsu
    Tsai, Ying-Huang
    Perng, Diahn-Warng
    Su, Wei-Juin
    Chou, Kun-Ta
    Su, Kang-Cheng
    Yen, Yung-Feng
    Chen, Pau-Chung
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (06) : 1927 - +
  • [9] LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
    Gong, Yiwen
    Sui, Zichao
    Lv, Yinghua
    Zheng, Qingshan
    Li, Lujin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (10) : 1321 - 1332
  • [10] A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD
    Lal, Chitra
    Strange, Charlie
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (17) : 1833 - 1843